Q: We are using a biosimilar for infliximab but it is manufactured by Merck/Samsung rather than Pfizer/Hospira. CMS requires that a manufacturer specific modifier be appended to the HCPCS code. Is there a new one for Merck/Samsung?
Q: For a ureteroscopy intended as a procedure with a biopsy and double-J stent, if the procedure ends when only the scope was placed before a biopsy was taken, could you just code ureteroscopy instead of coding it with the biopsy and the modifier -74?
Q: A clinic employee is being seen as a patient of the clinic for additional vaccinations. The medical assistant rooming the patient wants to review the vaccination history. Is this a HIPAA violation?
Q: My case management staff is having trouble communicating with the physicians at our facility. What skills can I teach my staff to improve communication?
Q: Can you explain where in the clinical documentation it would be acceptable to report from for Hierarchical Condition Category (HCC) purposes? Would you code from history of present illness, past medical history, active problem list, or the assessment?
